Last week, AstraZeneca hit a bump in the road as news of a failed lung cancer drug trial caused the share price to tumble. Investors were keen to know which funds were affected by the slump as well as the top income paying stocks, where to find undervalued companies and how to add alternatives to their portfolios.
Top 20 FTSE 350 Dividend Paying Stocks
UPDATED JUNE 2017: Dividend payments are expected to total £85bn in 2017. We reveal the top 20 dividend paying stocks in the FTSE 350
Top 20 FTSE 100 Dividend Paying Stocks
THE INCOME INVESTOR: The largest companies in the UK source their revenues internationally, meaning your dividend stream is boosted by global economic growth
The Morningstar Fair Value Estimate tells investors what the long-term, intrinsic value of a stock is. So which UK stocks are trading at less than their fair value?
Revealed: The Funds Hit by AstraZeneca Slump
Morningstar data reveals 17 equity income funds have overweight allocations to AstraZeneca in their portfolios, including star manager Neil Woodford
3 Gold Rated Funds Due a Bounce
Looking for a contrarian fund pick? These top-rated funds have underperformed peers in recent years - but could be due a change in fortune
Funds are suitable for investors who do not have the time or expertise to construct and monitor a portfolio themselves. We go back to basics and explain all
Finding Shares That Have Been Unfairly Punished
THE WEEK: Morningstar columnist Rodney Hobson is looking for buying opportunities after receiving a pay-out from now unlisted WS Atkins
3 Alternative Strategies for Your Portfolio
Henderson Alternative Strategies Trust fund manager Ian Barrass picks three top listed assets from his portfolio
How to Invest When Market Volatility Picks Up
Stock markets have been subdued recently, despite political unrest, but it is inevitable that greater volatility will emerge. The question is: how should we respond?
BMO: Why We’re Selling Passive Funds
With stock markets on either side of the Pond looking toppy, multi-asset fund managers Rob Burdett and Gary Potter are opting for active funds